TGM1

Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, August 7, 2023
NCT, Netherton syndrome, Cohort, Blue Cross Blue Shield Association, Neoplasm, Cystic fibrosis, Investigational New Drug, Phase 1, Investment, Patient, TGM1, Genetic distance, Medication, EMA, AATD, Phase, FDA, CF, UnitedHealth Group, Financial result, Form, Research, KRYS, Genotype, DEB, Medicaid, Inhalation, Clinical trial, Concha bullosa, Physician, Pharmaceutical industry, Clothing, Rolling (metalworking), Reinsurance, Security (finance), EU, IND

The study is on-going, and the Company plans to announce results from this study in the second half of 2023.

Key Points: 
  • The study is on-going, and the Company plans to announce results from this study in the second half of 2023.
  • Financial results for the quarter ended June 30, 2023:
    Cash, cash equivalents, and investments totaled $505.9 million on June 30, 2023.
  • For additional information on the Company’s financial results for the quarter ended June 30, 2023, please refer to the Form 10-Q filed with the SEC.
  • For additional information on the Company’s financial results for the six months ended June 30, 2023, please refer to the Form 10-Q filed with the SEC.

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Monday, May 8, 2023
NCT, Netherton syndrome, Cohort, European Medicines Agency, Ministry of Health, Labour and Welfare, Cystic fibrosis, Phase 1, Investment, Patient, Cystic Fibrosis Foundation, TGM1, Ministry of Health (Saudi Arabia), Association for Research in Vision and Ophthalmology, ARVO, Prescription Drug User Fee Act, Pannus, AATD, Rare, Jeune, FDA, IND, Skin, Safety, PIP, RDEB, Eye, Ministry, Financial result, Form, Research, Therapy, KRYS, DEB, MHLW, Clinical trial, Marketing, Annual general meeting, Pharmaceutical industry, Maple syrup, Ophthalmology, PDUFA, Health

Financial results for the quarter ended March 31, 2023:

Key Points: 
  • Financial results for the quarter ended March 31, 2023:
    Cash, cash equivalents, and investments totaled $355.5 million on March 31, 2023.
  • Research and development expenses for the quarter ended March 31, 2023 were $12.3 million, compared to $9.3 million for the quarter ended March 31, 2022.
  • General and administrative expenses for the quarter ended March 31, 2023 were $24.0 million, compared to $15.9 million for the quarter ended March 31, 2022.
  • For additional information on the Company’s financial results for the quarter ended March 31, 2023, please refer to the Form 10-Q filed with the SEC.

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

Retrieved on: 
Monday, February 27, 2023
Clinical trial, Safety, PDUFA, Netherton syndrome, Therapy, DEB, Perseverance, Form, Research, Krystal, European Medicines Agency, Securities and Exchange Commission (Philippines), IND, CF, The New England Journal of Medicine, BLA, Marketing, FDA, Investment, Patient, ASTRA, Dermatology, Security (finance), PIP, Quarter, NCT, EMA, AATD, Conference, MAA, NEJM, KRYS, TGM1, Prescription Drug User Fee Act, Cystic fibrosis, Primate, Cystic Fibrosis Foundation, Ageing, Pharmaceutical industry, Video game, Cryptocurrency

PITTSBURGH, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines, today reported financial results and key operational updates for the fourth quarter and year ending December 31, 2022.

Key Points: 
  • All clinical and manufacturing inspections conducted by the FDA as part of the BLA review process are now successfully complete.
  • In December 2022, the results of the B-VEC pivotal Phase 3 GEM-3 trial were published in the New England Journal of Medicine (NEJM).
  • Fourth Quarter and Full Year 2022 Financial Results:
    Cash, cash equivalents, and investments totaled $383.8 million on December 31, 2022.
  • For additional information on the Company’s financial results for the year ended December 31, 2022, please refer to the Form 10-K filed with the Securities and Exchange Commission.